

## Supplementary Table SI

### *Ex vivo* Panel


Markers	Fluorophore	Clone	Manufacturer	Function	Staining
Viability marker	Near Infra Red		Invitrogen	Exclusion	Surface
CD14	APC-Alexa750	Tuk4	Invitrogen	Exclusion	Surface
CD19	APC-Alexa750	SJ25-CI	Invitrogen	Exclusion	Surface
CD3	BV650	OKT3	BD Biosciences	Lineage	Surface
CD4	Alexa 488	OKT4	BD Biosciences	Lineage	Surface
CD45RA	PE-TEX Red	2H4	Beckman Coulter	Memory	Surface
CD27	Alexa 700	O323	eBioscience	Memory	Surface
CCR4	BV510	L291H4	Biologend	Homing	Surface
CCR6	BV605	G034E3	Biologend	Homing	Surface
CXCR3	PE-cy7	1C6/CXCR3	BD Biosciences	Homing	Surface
KLRG1	PerCP-eFluor 710	13F12F2	eBioscience	Activation	Surface
HLA-DR	eFluor 450	L243	eBioscience	Activation	Surface
PD-1	BV711	EH12.2H7	Biologend	Activation	Surface
MHC class II tetramer #1	PE		NIH	Mtb-specific CD4	Surface
MHC class II tetramer #2	APC		NIH	Mtb-specific CD4	Surface

### Functional Panel

Markers	Fluorophore	Clone	Manufacturer	Function	Staining
Viability marker	Near Infra Red		Invitrogen	Exclusion	Surface
CD14	APC-Alexa750	Tuk4	Invitrogen	Exclusion	Surface
CD19	APC-Alexa750	SJ25-CI	Invitrogen	Exclusion	Surface
CD3	BV650	OKT3	BD Biosciences	Lineage	ICS
CD4	Alexa 488	OKT4	BD Biosciences	Lineage	Surface
CCR4	BV510	L291H4	Biologend	Homing	Surface
CCR6	BV605	G034E3	Biologend	Homing	Surface
CXCR3	PE-cy7	1C6/CXCR3	BD Biosciences	Homing	Surface
KLRG1	PerCP-eFluor 710	13F12F2	eBioscience	Activation	Surface
HLA-DR	PE	L243	BD Biosciences	Activation	Surface
PD-1	BV711	EH12.2H7	Biologend	Activation	Surface
IFN- $\gamma$	Alexa 700	B27	BD Biosciences	Cytokine	ICS
TNF- $\alpha$	eFluor 450	MAb11	eBioscience	Cytokine	ICS
IL-2	PE/Dazzle 594	MQ1	Biologend	Cytokine	ICS
MHC class II tetramer	APC		NIH	Mtb-specific CD4	Surface

**Supplementary Table SI:** Detailed list of antibodies used in the flow cytometry panels.


Supplemental Figure S1




**Supplemental Figure S1: Validation of Mtb-specific MHC class II tetramer staining.** **A-** Example of the specificity of MHC class II tetramer labeling in two individuals. Tetramers loaded with the class II-associated invariant peptide (Clip, PVSKMRMATPLLMQA) were used as negative controls. **B-** Comparison of the performance of Mtb-specific MHC class II tetramers labeled with PE or APC. **C-** Example of dual MHC class II tetramer staining.

## Supplemental Figure S2

### A- Ex vivo phenotype



### B- Post-stimulation phenotype




**Supplemental Figure S2: Gating strategies.** **A-** Gating strategy used to define the phenotype of ex vivo Mtb-specific MHC class II CD4+ T cells. **B-** Gating strategy used to define the functional profile and phenotype of Mtb-specific CD4+ T cells in response to cognate Mtb peptides.

## Supplemental Figure S3

**A**

Groups	No. of screened individuals	No. TET responders	% responders	No. TET+ responses
LTBI/HIV-	28	13	46.4	19
LTBI/HIV+	30	11	36.7	19
aTB/HIV-	14	6	42.8	11
aTB/HIV+	14	5	35.7	10
<b>Total</b>	<b>86</b>	<b>34</b>	<b>40.0</b>	<b>59</b>



**Supplemental Figure S3: Identification and frequencies of Mtb-specific MHC class II tetramer (TET) responders and responses.** **A-** Summary table of the number of individuals screened, number of Mtb-specific MHC class II tetramer responders and number of tetramer responses identified in each clinical group. **B-** Comparison of the magnitude of each tested Mtb-specific MHC class II tetramer (DRB1\*0401/CFP-10, DRB5\*0101/CFP-10 and DQB1\*0602/ESAT-6 or CFP-10). The number on the x-axis represents the no. of TET+ responses / no. TET+ responders identified.